CorMedix vs Organogenesis
CRMD and ORGO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRMD and ORGO compare
CorMedix is the larger company, worth 3.6 times as much as Organogenesis ($376M against $103M).
CorMedix grew revenue faster over the last twelve months (281% versus 6.5% for Organogenesis).
CorMedix keeps more of each dollar of sales as profit, with a net margin of 40.5% compared with −18.4% at Organogenesis.
CorMedix scores higher on the StockData Score (13 against 9 for Organogenesis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRMD | ORGO |
|---|---|---|
| Size and price | ||
| Market cap | $376M | $103M |
| Share price | $4.82 | $0.803 |
| Change, 1 year | −57.0% | −87.1% |
| Change, 5 years | −4.9% | −91.9% |
| Beta (5Y) | 0.44 | 0.59 |
| Employees | 191 | 854 |
| StockData Score | ||
| Total score | 13 (better) | 9 |
| Valuation score | 1 | 1 |
| Growth score | 3 (better) | 0 |
| Performance score | 4 (better) | 3 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.8× | 0.2× (better) |
| P/B | 0.8× | 0.7× (better) |
| EV/EBITDA | 0.5× | – |
| P/FCF | 1.5× (better) | 5.0× |
| FCF yield | 66.7% (better) | 20.2% |
| Growth | ||
| Revenue growth (TTM) | 281% (better) | 6.5% |
| Revenue growth, 5Y average | 320% (better) | 10.8% |
| Net income growth (TTM) | 266% | – |
| EPS growth, 5Y average | – | 0.00% |
| Profitability | ||
| Gross margin | 82.8% | – |
| Operating margin | 47.0% (better) | −7.8% |
| Net margin | 40.5% (better) | −18.4% |
| FCF margin | 54.2% (better) | 4.6% |
| Return on equity | 54.9% (better) | −44.1% |
| Return on invested capital | 171% (better) | −21.7% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 2.56 | 3.52 (better) |
| Altman Z-score | 2.03 (better) | 1.26 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Buyback yield | −0.27% | – |
| Shareholder yield | −0.27% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 56.5% | 53.2% |
| Held by insiders | 3.2% | – |
| Insider net buying, 12 months | −$2.0M | −$988K (better) |
| Short interest, % of float | 18.8% | – |
Go deeper
- CRMD stock overview
- CRMD income statement
- CRMD valuation and score
- ORGO stock overview
- ORGO income statement
- ORGO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.